Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.

ABSTRACT: The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives to long-standing standards of care that include low-molecular-weight heparin and warfarin. The development of apixaban reflects a strategy to optimize the clinical pharmacology profile, dosing posology, trial designs, and statistical analyses across multiple indications, and to seek alignment with global health authorities. The primary objective of dose selection was to maintain balance between efficacy and bleeding risk. Twice-daily dosing of apixaban, rather than once daily, was chosen to lower peak concentrations and reduce fluctuations between peak and trough levels. Our discussion here focuses on the use of apixaban for stroke prevention in nonvalvular atrial fibrillation (NVAF). Supporting t

SUBMITTER: Hanna MS 

PROVIDER: S-EPMC4260137 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature